静脉注射免疫球蛋白治疗某些皮肤病的进展

Intravenous immunoglobulin for the treatment of some dermatoses

最初静脉注射免疫球蛋白批准用于原发性免疫缺陷病的抗体替代治疗，随着对其作用机制的进一步认识，静脉注射免疫球蛋白用于治疗大疱性皮肤病、结缔组织病、重症药疹、川崎病等疾病，证实疗效好，提高了患者生存率；其相对安全性高，耐受性好，但也有一些不良反应。目前最大的缺陷是缺乏大样本的随机对照试验。

Intravenous immunoglobulin （IVIG） was initially approved as an alternative to antibodies in the treatment of primary immunodeficiency diseases. With further insights into its action mechanism, IVIG has been successfully applied to the treatment of bullous dermatoses, connective tissue diseases, severe drug eruptions, Kawasaki disease, etc. It has been proved that IVIG has good therapeutic effect and increases the survival of patients. Although IVIG is relatively safe and well tolerable, it has some adverse effects. Currently, lack of large-scale randomized controlled trials （RCTs） remains the biggest problem.